文献速递白血病造血干细胞移植与细胞治疗MDS 与骨髓增殖性肿瘤

急性髓系白血病克隆性造血与可测量残留病评估

Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia.
PubMed 文献 · Blood · 2020-01-01

本文综述急性髓系白血病(AML)治疗后克隆性造血(CH)对可测量残留病(MRD)判读的影响。AML达完全缓解后检出的CH包括真性残留或早期复发AML、骨髓增生异常综合征或AML祖先克隆、以及潜能不明的独立或新发克隆。文中提出术语标准化建议,并回顾异基因造血干细胞移植后供者来源克隆等各类治疗后造血克隆的临床数据与不确定领域。

要点

  • AML达完全缓解后检出的克隆性造血不等同于残留AML,需区分克隆类型判读MRD。
  • AML相关突变持续存在多项研究显示可预示复发,其他类型CH的临床意义尚不明确。
  • 异基因造血干细胞移植后克隆可来源于供者,个别可引发与受者原AML克隆无关的新髓系肿瘤。

核心结论

  • AML治疗后检出的克隆性造血谱系多样,并非均反映残留AML,MRD判读需结合克隆来源与类型。
  • AML相关突变的存在在多项研究中被显示为复发的先兆,而其他类型CH的意义了解较少。
  • 异基因造血干细胞移植后出现的克隆可为供者来源,部分可导致与受者原AML克隆无关的新髓系肿瘤。

研究设计与样本

  • 本文为综述,讨论接受治疗的AML患者中可检测到的克隆性造血谱系,并提出该情形下的术语标准化建议。
  • 文章回顾了各类治疗后造血克隆的临床数据及不确定性领域,并涉及异基因造血干细胞移植后的克隆分析。

主要发现

  • AML达完全缓解后检出的CH包括真性残留或早期复发AML、骨髓增生异常综合征或AML祖先性CH,以及潜能不明的独立或新发克隆。
  • AML相关突变的存在在多项研究中被显示预示复发,其他类型CH的临床意义尚不明确。
  • 移植后克隆可为供者来源,部分可引发与受者原AML克隆无关的新髓系肿瘤。

临床怎么用

  • 解读AML患者MRD结果时应区分克隆类型,避免将非AML相关的克隆性造血误判为残留病。
  • 对AML相关突变持续存在的患者应关注复发风险,其他类型CH需结合系列监测与临床背景判断。
  • 移植后检出克隆需考虑供者来源可能,并警惕与受者原AML克隆无关的新髓系肿瘤。

局限性

  • 多种治疗后造血克隆的临床意义尚不明确,尤其非AML相关类型CH的预后价值了解较少。
  • 文中未提供统一的克隆判读阈值与标准化检测方案,术语标准化仍为建议性质。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Current objectives regarding treatment of acute myeloid leukemia (AML) include achieving complete remission (CR) by clinicopathological criteria followed by interrogation for the presence of minimal/measurable residual disease (MRD) by molecular genetic and/or flow cytometric techniques. Although advances in molecular genetic technologies have enabled highly sensitive detection of AML-associated mutations and translocations, determination of MRD is complicated by the fact that many treated patients have persistent clonal hematopoiesis (CH) that may not reflect residual AML. CH detected in AML patients in CR includes true residual or early recurrent AML, myelodysplastic syndrome or CH that is ancestral to the AML, and independent or newly emerging clones of uncertain leukemogenic potential. Although the presence of AML-related mutations has been shown to be a harbinger of relapse in multiple studies, the significance of other types of CH is less well understood. In patients who undergo allogeneic hematopoietic cell transplantation (HCT), post-HCT clones can be donor-derived and in some cases engender a new myeloid neoplasm that is clonally unrelated to the recipient's original AML. In this article, we discuss the spectrum of CH that can be detected in treated AML patients, propose terminology to standardize nomenclature in this setting, and review clinical data and areas of uncertainty among the various types of posttreatment hematopoietic clones.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Hasserjian RP, Steensma DP, Graubert TA, et al. Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia. Blood. 2020. PMID: 32232484. doi:10.1182/blood.2019004770

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。